Rhamnogalacturonan II is a Toll-like receptor 4 agonist that inhibits tumor growth by activating dendritic cell-mediated CD8+ T cells
Experimental & Molecular Medicine
; : e8-2013.
Article
in En
| WPRIM
| ID: wpr-199828
Responsible library:
WPRO
ABSTRACT
We evaluated the effectiveness of rhamnogalacturonan II (RG-II)-stimulated bone marrow-derived dendritic cells (BMDCs) vaccination on the induction of antitumor immunity in a mouse lymphoma model using EG7-lymphoma cells expressing ovalbumin (OVA). BMDCs treated with RG-II had an activated phenotype. RG-II induced interleukin (IL)-12, IL-1beta, tumor necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma) production during dendritic cell (DC) maturation. BMDCs stimulated with RG-II facilitate the proliferation of CD8+ T cells. Using BMDCs from the mice deficient in Toll-like receptors (TLRs), we revealed that RG-II activity is dependent on TLR4. RG-II showed a preventive effect of immunization with OVA-pulsed BMDCs against EG7 lymphoma. These results suggested that RG-II expedites the DC-based immune response through the TLR4 signaling pathway.
Key words
Full text:
1
Index:
WPRIM
Main subject:
Phenotype
/
Dendritic Cells
/
Acute-Phase Proteins
/
Bone Marrow Cells
/
Membrane Glycoproteins
/
Lymphocyte Activation
/
T-Lymphocytes, Cytotoxic
/
Signal Transduction
/
Carrier Proteins
/
Cell Differentiation
Type of study:
Prognostic_studies
Limits:
Animals
Language:
En
Journal:
Experimental & Molecular Medicine
Year:
2013
Type:
Article